Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650011 | 0.85 | FFAR2 (0.34) | TSHRFFAR2BACE1 | |
| SCHEMBL7653080 | 0.85 | FFAR2 (0.34) | TSHRFFAR2BACE1 | |
| SCHEMBL4029679 | 0.85 | GPX4 (0.35) | MEN1KMT2ABACE1 | |
| SCHEMBL3299155 | 0.82 | GPX4 (0.34) | — | |
| SCHEMBL3297618 | 0.82 | GPX4 (0.34) | MEN1KMT2ABACE1 | |
| SCHEMBL3298446 | 0.82 | GPX4 (0.34) | — | |
| SCHEMBL5075689 | 0.80 | MEN1 (0.40) | MEN1KMT2AMCHR1TSHRFFAR2 | |
| SCHEMBL5081600 | 0.80 | MEN1 (0.40) | MEN1KMT2AMCHR1TSHRFFAR2 | |
| SCHEMBL5078924 | 0.80 | MEN1 (0.40) | MEN1KMT2AMCHR1TSHRFFAR2 | |
| SCHEMBL3295171 | 0.79 | HSD17B10 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | MEN1 1024/4885KMT2A 2406/4885MCHR1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.